Company profile

Daniel O'Day
Incorporated in
Fiscal year end
IRS number

GILD stock data

FINRA relative short interest over last month (20 trading days) ?


5 Nov 19
19 Feb 20
31 Dec 20


Company financial data Financial data

Quarter (USD) Sep 19 Jun 19 Mar 19 Dec 18
Revenue 5.6B 5.69B 5.28B 5.8B
Net income -1.17B 1.88B 1.98B 3M
Diluted EPS -0.92 1.47 1.54 0
Net profit margin -20.79% 33.07% 37.40% 0.05%
Operating income -1.47B 2.43B 2.24B 1.14B
Net change in cash -1.77B -5.69B -1.01B 3.37B
Cash on hand 9.47B 11.24B 16.93B 17.94B
Cost of revenue 1.04B 1B 957M 1.57B
Annual (USD) Dec 18 Dec 17 Dec 16 Dec 15
Revenue 22.13B 26.11B 30.39B 32.64B
Net income 5.46B 4.63B 13.5B 18.11B
Diluted EPS 4.17 3.51 9.94 11.91
Net profit margin 24.65% 17.73% 44.43% 55.48%
Operating income 8.2B 14.12B 17.63B 22.19B
Net change in cash 15.54B -100M -200M 600M
Cash on hand 17.94B 2.4B 2.5B 2.7B
Cost of revenue 4.85B 4.37B 4.26B 4.01B

Financial data from company earnings reports

79.2% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 1433 1445 -0.8%
Opened positions 97 115 -15.7%
Closed positions 109 128 -14.8%
Increased positions 568 548 +3.6%
Reduced positions 588 636 -7.5%
13F shares
Current Prev Q Change
Total value 873.29B 749.23B +16.6%
Total shares 1B 1.01B -0.4%
Total puts 15.37M 13.56M +13.3%
Total calls 10.46M 11.11M -5.8%
Total put/call ratio 1.5 1.2 +20.3%
Largest owners
Shares Value Change
Vanguard 102.49M $6.5B +0.4%
BLK BlackRock 100M $6.34B +0.1%
Capital Research Global Investors 76.79M $4.87B -6.1%
STT State Street 57.38M $3.64B -0.2%
BK Bank Of New York Mellon 28.2M $1.79B -0.7%
IVZ Invesco 23M $1.46B +0.1%
Capital World Investors 21.23M $1.35B -2.3%
Geode Capital Management 18.69M $1.18B +1.7%
Dodge & Cox 17.44M $1.11B +1.2%
NTRS Northern Trust 17.13M $1.09B -0.3%
Largest transactions
Shares Bought/sold Change
FHI Federated Hermes 5.58M +5.32M +2045.8%
Capital Research Global Investors 76.79M -4.96M -6.1%
FMR 8.24M -4.47M -35.2%
BEN Franklin Resources 16.31M +3.72M +29.5%
Alliancebernstein 8.9M -2.25M -20.2%
Capital International Investors 12.33M +2.23M +22.1%
Millennium Management 43.42K -2.17M -98.0%
Renaissance Technologies 14.73M +1.99M +15.7%
Arrowstreet Capital, Limited Partnership 1.78M -1.82M -50.6%
FIL 370.38K -1.74M -82.4%

Financial report summary

  • A substantial portion of our revenues is derived from sales of our HIV and HCV products. If we are unable to increase HIV sales or if HCV sales decrease more than anticipated, then our results of operations may be adversely affected.
  • If we fail to develop and commercialize new products or expand the indications for existing products, our prospects for future revenues and our results of operations may be adversely affected.
  • Our inability to accurately predict demand for our products and fluctuations in purchasing patterns or wholesaler inventories makes it difficult for us to accurately forecast sales and may cause our forecasted revenues and earnings to fluctuate, which could adversely affect our financial results and stock price.
  • Yescarta, a chimeric antigen receptor (CAR) T cell therapy, represents a novel approach to cancer treatment that creates significant challenges for us, which may impact our ability to increase sales of Yescarta.
  • Our results of operations may be adversely affected by current and potential future healthcare legislative and regulatory actions.
  • Our existing products are subject to reimbursement from government agencies and other third parties, and we may be required to provide rebates and other discounts on our products, which may result in an adjustment to our product revenues. Pharmaceutical pricing and reimbursement pressures may adversely affect our profitability and our results of operations.
  • Laws and regulations applicable to the health care industry could impose new obligations on us, require us to change our business practices and restrict our operations in the future.
  • We have engaged in, and may in the future engage in, business acquisitions, licensing arrangements, collaborations, disposal of our assets and other strategic transactions, which could cause us to incur significant expenses and could adversely affect our financial condition and results of operations.
  • Approximately 26% of our product sales occur outside the United States, and currency fluctuations and hedging expenses may cause our earnings to fluctuate, which could adversely affect our stock price.
  • If significant safety issues arise for our marketed products or our product candidates, our reputation may be harmed and our future sales may be reduced, which could adversely affect our results of operations.
  • Our operations depend on compliance with complex FDA and comparable international regulations. Failure to obtain broad approvals on a timely basis or to maintain compliance could delay or halt commercialization of our products.
  • We face risks in our clinical trials, including the potential for unfavorable results, delays in anticipated timelines and disruption, which may adversely affect our prospects for future revenue growth and our results of operations.
  • We depend on relationships with third parties for sales and marketing performance, technology, development, logistics and commercialization of products. Failure to maintain these relationships, poor performance by these companies or disputes with these third parties could negatively impact our business.
  • Our success depends to a significant degree on our ability to defend our patents and other intellectual property rights both domestically and internationally. We may not be able to obtain effective patents to protect our technologies from use by competitors.
  • Our success depends in large part on our ability to operate without infringing upon the patents or other proprietary rights of third parties.
  • Manufacturing problems, including at our third-party manufacturers and corporate partners, could cause inventory shortages and delay product shipments and regulatory approvals, which may adversely affect our results of operations.
  • We may not be able to obtain materials or supplies necessary to conduct clinical trials or to manufacture and sell our products, which could limit our ability to generate revenues.
  • Imports from countries where our products are available at lower prices and unapproved generic or counterfeit versions of our products could have a negative impact on our reputation and business.
  • Expensive litigation and government investigations have increased our expenses which may continue to reduce our earnings.
  • We may face significant liability resulting from our products and such liability could materially reduce our earnings.
  • If we fail to attract, develop and retain highly qualified personnel, our business and operations may be adversely affected.
  • Business disruptions from natural or man-made disasters may adversely affect our revenues and materially reduce our earnings.
  • We are dependent on information technology systems, infrastructure and data, which may be subject to cyberattacks and security breaches.
  • Changes in our effective income tax rate could reduce our earnings.
  • There can be no assurance that we will pay dividends or continue to repurchase stock.
Management Discussion
  • This Quarterly Report on Form 10-Q contains forward-looking statements regarding future events and our future results that are subject to the safe harbors created under the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended. The forward-looking statements are contained principally in this section entitled “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and “Risk Factors.” Words such as “expect,” “anticipate,” “target,” “goal,” “project,” “hope,” “intend,” “plan,” “believe,” “seek,” “estimate,” “continue,” “may,” “could,” “should,” “might,” variations of such words and similar expressions are intended to identify such forward-looking statements. In addition, any statements other than statements of historical fact are forward-looking statements, including statements regarding overall trends, operating cost and revenue trends, liquidity and capital needs, collaboration and licensing arrangements and other statements of expectations, beliefs, future plans and strategies, anticipated events or trends and similar expressions. We have based these forward-looking statements on our current expectations about future events. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Our actual results may differ materially from those suggested by these forward-looking statements for various reasons, including those identified below under “Risk Factors.” Given these risks and uncertainties, you are cautioned not to place undue reliance on forward-looking statements. The forward-looking statements included in this report are made only as of the date hereof. Except as required under federal securities laws and the rules and regulations of the Securities and Exchange Commission (SEC), we do not undertake and specifically decline any obligation to update any of these statements or to publicly announce the results of any revisions to any forward-looking statements after the distribution of this report, whether as a result of new information, future events, changes in assumptions or otherwise. In evaluating our business, you should carefully consider the risks described in the section entitled “Risk Factors” under Part II, Item 1A in addition to the other information in this Quarterly Report on Form 10-Q. Any of the risks contained herein could materially and adversely affect our business, results of operations and financial condition.
Content analysis ?
H.S. sophomore Good
New words: Andrew, began, Belgium, biomarker, Brett, capping, Chairman, Christi, Counsel, culture, diabetic, Dickinson, Floria, Glympse, greatest, highest, IDWeek, influence, integrase, Italy, Japanese, Johanna, Jyoti, kg, Labor, Luxembourg, Mehra, Mercier, Merdad, metropolitan, organizational, Parsey, Pletcher, receptive, renal, sclerosing, sex, Shaw, Spain, sublicensable, Submission, subset, vaginal, weighing, workplace
Removed: achieving, correctly, French, German, indefinite, institute, IRS, John, July, lived, mg, Mylan, Natco, relation, remain, revoke, Rheumatology, role, ruled, selection, staying, successor, Virginia, West